Key result
Premature ventricular complex burden ≥1% in pregnant women with structurally normal hearts was not associated with increased composite adverse maternal and neonatal events compared to controls.
Why the study?
High PVC burden may increase the risk of left ventricular dysfunction and all-cause mortality, but maternal and neonatal outcomes in pregnant women with structurally normal hearts and PVC burden >=1% remained to be evaluated.
Does frequent premature ventricular complex (PVC) burden increase adverse maternal and neonatal outcomes in pregnant women with structurally normal hearts?
Cohort (n=321)
Does frequent premature ventricular complex (PVC) burden increase adverse maternal and neonatal outcomes in pregnant women with structurally normal hearts?
In pregnant women with structurally normal hearts, frequent PVCs are generally benign and not associated with an increase in composite adverse maternal or neonatal outcomes, avoiding the need for antiarrhythmic drugs.
BACKGROUND: High premature ventricular complex (PVC) burden may increase the risk of left ventricular dysfunction and all-cause mortality. We aimed to evaluate maternal and neonatal outcomes of pregnant women with structurally normal heart having PVC burden ≥1%. METHODS: This retrospective cohort study used data from Chang Gung Research Database. Pregnancies from January 1, 2005, through June 30, 2020, with documented maternal PVC burden ≥1% by 24-h Holter monitor were identified. Pregnant women with a diagnosis of structural heart disease or arrhythmias other than PVC were excluded. We used propensity score matching (PSM) to balance the covariates between the PVC group and normal control group. The PVC group was classified into low-PVC (<10%) and high-PVC burden subgroups. The maternal and neonatal outcomes were assessed through 6 months after delivery or termination. RESULTS: After PSM, there were 214, 61, and 46 pregnant women enrolled in the normal control group, low-PVC burden, and high-PVC burden subgroups, respectively. The high-PVC and low-PVC burden subgroups had composite adverse maternal and neonatal events similar to the control group without use of antiarrhythmic drugs (AADs), but a higher proportion of placental abruption was observed in the high-PVC burden subgroup. Maternal age, diabetes, and overweight were significant predictors of composite adverse maternal events, whereas only maternal age was a significant predictor of composite adverse neonatal events. CONCLUSIONS: High PVC burden was not associated with poor composite adverse maternal and neonatal outcomes with no need of AADs therapy in pregnant women with structurally normal heart.
No takes yet. Share an insight, caveat, or question.
Chou et al. (2022) conducted a cohort in Frequent premature ventricular complexes in pregnancy (n=321). Premature ventricular complex (PVC) burden ≥1% vs. Normal control group was evaluated on Composite adverse maternal and neonatal events. Premature ventricular complex burden ≥1% in pregnant women with structurally normal hearts was not associated with increased composite adverse maternal and neonatal events compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: